KeyBanc raises ResMed stock price target on FY27 outlook confidence

This is a multiple-expansion setup more than a near-term earnings revision story. The important mechanism is that buybacks plus high recurring cash flow can support a floor even if top-line growth stays only mid-single digits, so incremental confidence on outer-year visibility matters more than the latest quarter miss. In other words, the stock is sensitive to the market’s willingness to pay up for durability; if management keeps reinforcing FY27/FY30 targets, the valuation debate can shift from “is growth decelerating?” to “how much is the platform worth through the cycle?”

The key loser in the ecosystem is not a single named rival but any legacy sleep-apnea supplier relying on price competition or channel share to offset category headwinds. If GLP-1 adoption is truly slowing new patient flow, the second-order effect is that the market will discount not just unit growth but installed-base replacement economics; that would pressure the entire sleep-device group’s multiples, not just this name. Conversely, if obesity-drug penetration increases screening and diagnosis rates, the consensus bearish GLP-1 narrative may be overstated: more treated obesity could enlarge the addressable pool of diagnosed sleep apnea patients over 6-18 months.

The immediate catalyst window is 1-3 months: next prints, channel commentary, and any evidence that share repurchases are offsetting moderation in organic growth. The main falsifier is not valuation—it is either a downward revision to outer-year visibility or a sign that U.S. competitive intensity is forcing pricing/volume tradeoffs. If the stock fails to hold the low-230s after the next update, the market is likely saying the re-rating case is capped until there is harder evidence of accelerating growth, regardless of analyst target moves.